Studying on the progress of cardiotoxicity induced by PD-1/PD-L1 immune checkpoint inhibitors
- Autores: Xinyi Y.1, Reshetov I.V.1, Poltavskaya M.G.1, Agakina Y.S.1, Kulikov T.S.1
-
Afiliações:
- University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)
- Edição: Volume 31, Nº 9 (2024)
- Páginas: 155-160
- Seção: Коморбидность
- URL: https://journals.eco-vector.com/2073-4034/article/view/680165
- DOI: https://doi.org/10.18565/pharmateca.2024.9.155-160
- ID: 680165
Citar
Texto integral



Resumo
Cardiotoxicity (CT) is a serious side effect of anticancer drugs, especially death receptor 1 (PD-1) or death ligand 1 (PD-L1). Immune checkpoint inhibitors (ICIs) have attracted wide attention in recent years. This article describes the progress in studying CT induced by PD-1 and PD-1/PD-L1 ICIs. An overview of PD-1 and PD-1/PD-L1 immune checkpoint inhibitors, their CT manifestations, potential mechanisms, diagnostic and therapeutic methods are presented.
Palavras-chave
Texto integral

Sobre autores
Yang Xinyi
University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)
Autor responsável pela correspondência
Email: xinyiyang@yandex.ru
ORCID ID: 0009-0009-2320-0834
PhD student, Department of Oncology, Reconstructive Surgery and Radiology
Rússia, MoscowI. Reshetov
University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: xinyiyang@yandex.ru
Rússia, Moscow
M. Poltavskaya
University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: xinyiyang@yandex.ru
Rússia, Moscow
Yu. Agakina
University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: xinyiyang@yandex.ru
Rússia, Moscow
T. Kulikov
University Clinical Hospital No. 1, I.M. Sechenov First Moscow State Medical University (Sechenov University)
Email: xinyiyang@yandex.ru
Rússia, Moscow
Bibliografia
- Beyer A.M., Bonini M.G., Moslehi J. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. Am J Physiol Heart Circ Physiol. 2019;317(1):H164–Н1677. doi: 10.1152/ajpheart.00277.2019.
- Xia L., Liu Y., Wang Y.. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions. Oncologist 2019;24(Suppl. 1):S31–S41. doi: 10.1634/theoncologist.2019-IO-S1-s05.
- Spallarossa P., Meliota G., Brunelli C., et al. Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. Med Res Rev. 2018;38(5):1447–68. doi: 10.1002/med.21478.
- Inno A., Metro G., Bironzo P., et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori. 2017;103(5):405–21. doi: 10.5301/tj.5000625.
- Wu Y., Lin L., Liu X. Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors. Dis Markers. 2020;2020:7291586. doi: 10.1155/2020/7291586.
- Khunger A., Battel L., Wadhawan A., et al. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. Curr Oncol Rep. 2020;22(7):65. doi: 10.1007/s11912-020-00925-8.
- Lyon A.R., Yousaf N., Battisti N.M.L., et al. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet. Oncol. 2018;19(9):447–58. doi: 10.1016/S1470-2045(18)30457-1.
- Boussiotis V.A. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. N Engl J Med 2016;375(18):1767–78. doi: 10.1056/NEJMra1514296.
- Varricchi G., Galdiero M.R., Marone G., et al. Cardiotoxicity of immune checkpoint inhibitors. ESMO Open. 2017;2(4):e000247. doi: 10.1136/esmoopen-2017-000247.
- Varricchi G., Marone G., Mercurio V., et al. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. Curr Med Chem. 2018;25(11):1327–39. doi: 10.2174/0929867324666170407125017.
- Boutros C., Tarhini A., Routier E., et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13(8):473–86. doi: 10.1038/nrclinonc.2016.58.
- Spain L., Walls G., Julve M., et al. Neurotoxicity from immunecheckpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann. Oncol. 2017;28(2):377–85. doi: 10.1093/annonc/mdw558.
- Michot J.M., Bigenwald C., Champiat S., et al. Immune–related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer.2016;54:139–48.
- Zhang J.C., Chen W.D., Alvarez J.B., et al. Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. Acta Pharmacol. Sinica. 2018;39(11):1693–98. doi: 10.1038/s41401-018-0062-2.
- Johnson D.B., Balko J.M., Compton M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55. doi: 10.1056/NEJMoa1609214.
- Choi J., Lee S.Y. Clinical Characteristics and Treatment of ImmuneRelated Adverse Events of Immune Checkpoint Inhibitors. Immune Netw. 2020;20(1):e9. doi: 10.4110/in.2020.20.e9.
- Zhang C., Liu Y., Wang H., et al. Real-world Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study. Scientific Reports. 2024;14(5):76829. doi: 10.1038/s41598-024-76829-5.
- Konala V.M., Adapa S., Aronow W.S. Immune Checkpoint InhibitorsRelated Cardiotoxicity. Am J Ther. 2020;27(6):e591–e598. doi: 10.1097/MJT.0000000000000988.
- Zhou Y.W., Zhu Y.J., Wang M.N., et al. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. Front Pharmacol. 2019;10:1350. doi: 10.3389/ fphar.2019.01350.
- Baraibar I., Melero I., Ponz-Sarvise M., et al. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. Drug Saf. 2019;42(2):281–94. doi: 10.1007/s40264-018-0774-8.
- Chen D.Y., Huang W.K., Chien-Chia Wu V., et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119(10):1461–75. doi: 10.1016/j.jfma.2019.07.025.
- Palaskas N., Lopez-Mattei J., Durand J.B., et al. Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. J Am Heart Assoc. 2020;9(2):e013757. doi: 10.1161/JAHA.119.013757.
- Raikhelkar J., Uriel N. Immune checkpoint inhibitor myocarditis. Curr Opin Cardiol. 2019;34(3):303–6. doi: 10.1097/HCO.0000000000000622.
- Peleg Hasson S., Salwen B., Sivan A., et al. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. Clin Res Cardiol. 2020;110(1):50–60. doi: 10.1007/s00392-020-01648-3.
- Slawinski G., Wrona A., Dabrowska-Kugacka A., et al. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. Int J Mol Sci. 2020;21(19):7195. doi: 10.3390/ijms21197195.
- Mahmood S.S., Fradley M.G., Cohen J.V., et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755–64. doi: 10.1016/j.jacc.2018.02.037.
- Altan M., Toki M.I., Gettinger S.N., et al. Immune Checkpoint Inhibitor-Associated Pericarditis. J Thorac Oncol. 2019;14(6):1102–8. doi: 10.1016/j.jtho.2019.02.026.
- Trontzas I.P., Vathiotis I.A., Kyriakoulis K.G., et al. Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases. Cancers (Basel). 2023;15(9):2637. doi: 10.3390/cancers15092637.
- Shalata W., Abu-Salman A., Steckbeck R., et al. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers (Basel). 2021;13(20):5218. doi: 10.3390/cancers13205218.
- Sarocchi M., Grossi F., Arboscello E., et al. Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. Oncologist. 2018;23(8):936–42. doi: 10.1634/theoncologist.2017-0452.
- Martin Huertas R., Saavedra Serrano C., Perna C., et al. Cardiac toxicity of immune-checkpoint inhibitors: A clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges. Cancer Manag Res. 2019;11:4541–8. doi: 10.2147/CMAR.S185202.
- Zlotoff D.A., Hassan M.Z.O., Zafar A., et al. Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. J Immunother Cancer. 2021;9(3):e002007. doi: 10.1136/jitc-2020-002007.
- Poto R., Troiani T., Criscuolo G., et al. Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. Front Immunol. 2022;13:804597. doi: 10.3389/fimmu. 2022.804597.
- Ganesh S., Zhong P., Zhou X. Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. Front Cardiovasc Med. 2022;9:997660. doi: 10.3389/fcvm.2022.997660.
Arquivos suplementares
